Combinatietherapie bij reumatoide artritis: Prioriteiten voor toekomstig onderzoek [Combination Therapy in Rheumatoid Arthritis: Priorities for Future Research]
Jan 1, 2001
|PDF file||0.3 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
This review is part of a study for the Dutch Health Care Insurance Council to develop a generic method for examining combinations of medications. The study uses the RAND Appropriateness Method to determine where clinical research on pharmaceutical combinations is needed by evaluating the existing published evidence and clinical expertise about the use of these combinations. This generic method is to be pilot-tested by addressing the problem of prioritizing clinical research on combination medications for rheumatoid arthritis.
Note: this study is part of a larger RAND Europe study that is also available online. Please see related link.
This report is part of the RAND Corporation RAND Europe document series. RAND Europe reports (RE) were monograph/reports (MR) produced by RAND Europe. REs were published at RAND from 1998 to 2001. RAND monograph/reports presented major research findings that addressed the challenges facing the public and private sectors.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.